Literature DB >> 16366361

[Yersinia pseudotuberculosis type 4a infection meeting the diagnostic criteria for Kawasaki disease complicated by disseminated intravascular coagulation].

Daisuke Usui1, Yoshiki Ishii, Hiroto Akaike, Hiroshi Isumi, Hayasi Komura, Kouzou Kawasaki, Kazunobu Ouchi.   

Abstract

We report a case of Yersinia pseudotuberculosis (Y. ptbc) infection complicated by disseminated intravascular coagulation (DIC) that presented as Kawasaki disease (KD). A 9-year-old girl had been well until two days before, when she developed a fever, exanthem, and abdominal pain. An erythematous macular rash was observed in the perineum, and she had a strawberry tongue. The patient was admitted to Kawasaki Medical School Hospital because the macular rash spread over her entire body, and edema of her hands and conjunctivitis subsequently developed. Echo cardiography showed dilation of the left coronary artery. Thrombocytopenia and an elevated total fibrin degeneration product level were noted on the third hospital day, and the prothronmbin and partial-thromboplastin times were prolonged. Her clinical presentation was typical of KD and DIC. A stool culture and a blood culture were negative. Serologic tests were positive for antibodies to Y. ptbc. The antibody titer against Y. ptbc-derived mitogen was not elevated after her recovery. Y. ptbc infection should be considered in an older child whose clinical findings fulfill the criteria for KD complicated by DIC.

Entities:  

Mesh:

Year:  2005        PMID: 16366361     DOI: 10.11150/kansenshogakuzasshi1970.79.895

Source DB:  PubMed          Journal:  Kansenshogaku Zasshi        ISSN: 0387-5911


  2 in total

1.  Kawasaki disease with DIC as a complication.

Authors:  V K Parvathy; A Davis Manuel; S Criton; G Rajesh
Journal:  Indian J Pediatr       Date:  2007-11       Impact factor: 1.967

Review 2.  Kawasaki Disease: The Role of Immune Complexes Revisited.

Authors:  Stephanie Menikou; Paul R Langford; Michael Levin
Journal:  Front Immunol       Date:  2019-06-12       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.